血栓调节蛋白的研究进展

中国临床药理学与治疗学 ›› 2015, Vol. 20 ›› Issue (4): 445-449.

血栓调节蛋白的研究进展

李宸宇¹, 孙晓红², 王丽³, 李华³

¹大连医科大学第一临床学院,大连 116044,辽宁;
²中国人民解放军第210医院药剂科,大连 116015,辽宁;
³大连医科大学药学院药理教研室,大连 116044,辽宁

收稿日期:2014-12-30 修回日期:2015-03-20 发布日期:2015-05-07
通讯作者: 李华,女,博士,教授,硕士生导师,研究方向:心血管及糖尿病药理学。Tel: 0411-86110406 E-mail: dllihua@126.com
作者简介:李宸宇男,硕士研究生在读,研究方向:消化内科学。E-mail: 893424515@qq.com
基金资助:
辽宁省高等学校优秀人才支持计划(高校杰出青年学者成长计划)资助。

Progress in thrombomodulin researches

LI Chen-yu¹, SUN Xiao-hong², WANG li³, LI Hua³

¹ The First Affiliated Hospital of Dalian Medical University,Dalian 116044, Liaoning, China;
² Pharmacy Department of the Chinese People's Liberationarmy 210 Hospital, Dalian 116015, Liaoning, China;
³ Pharmacology Teaching and Research Section at the Dalian Mecical University School of Medicine, Dalian 116044, Liaoning, China

Received:2014-12-30 Revised:2015-03-20 Published:2015-05-07

摘要/Abstract

摘要： 血栓调节蛋白(thrombomodulin,TM)主要表达于血管内皮细胞。血管内皮细胞受损后引起TM的异常表达并释放入血。因此TM被认为是内皮细胞损伤的一种标志物,并与许多疾病的发生、发展有着密切关系。本文对近年来有关TM的研究按照抗炎作用、维持上皮细胞形态、改善血液系统疾病、改善移植及抗肿瘤等方面进行综述。这些研究提示TM不仅对多种疾病有诊断、预后意义,也可能成为这些疾病重要的治疗靶点或治疗药物,具有广阔的临床应用前景。

关键词: 血栓调节蛋白, 抗炎, 血液疾病, 肿瘤

Abstract: Thrombomodulin(TM)is expressed mainly in vascular endothelium. The injury on endothelium causes the abnormal expression of TM and secretion of TM into blood. Therefore, TM is accepted as the marker for endothelial injury and associated with the initiation and developments of many kinds of disease. The present review summarized the recent advances of TM on anti-inflammation, maintaining epithelial morphology, improving hematopathy and transplantation, and anti-tumor effects. These findings suggest that TM not only possess diagnostic and prognostic significance, but also become the important therapeutic target or agent for many kinds of diseases.

Key words: thrombomodulin, anti-inflammation, hematopathy, tumor

中图分类号:

R966

李宸宇, 孙晓红, 王丽, 李华. 血栓调节蛋白的研究进展[J]. 中国临床药理学与治疗学, 2015, 20(4): 445-449.

LI Chen-yu, SUN Xiao-hong, WANG li, LI Hua. Progress in thrombomodulin researches[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(4): 445-449.

参考文献

[1] Anastasiou G, Gialeraki A, Merkouri E, et al. Thrombomodulin as a regulator of the anticoagulant pathway: implication in the development of thrombosis[J]. Blood Coagul Fibrinolysis, 2012, 23(1):1-10.
[2] Wei HJ, Li YH, Shi GY, et al. Thrombomodulin domains attenuate atherosclerosis by inhibiting thrombin-induced endothelial cell activation[J]. Cardiovasc Res,2011, 92(2):317-327.
[3] Leung LL, Myles T, Nishimura T, et al. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI)[J]. Mol Immunol,2008:632, 61-69.
[4] Ruf W, Furlan-Freguia C, Niessen F. Vascular and dendritic cell coagulation signaling in sepsis progression[J]. J Thromb Haemost, 2009, 7(1):118-121.
[5] Maeda S, Takahashi S, Sato M. Serum thrombomodulin as a newly identified biomarker for postoperative lung injury:a prospective observational study[J]. Tohoku J Exp Med, 2012,228(2):135-141.
[6] Hsu YY, Shi GY, Kuo CH, et al. Thrombomodulin is an ezrin-interacting protein that controls epithelial morphology and promotes collective cell migration[J]. FASEB J,2012,26(8): 3440-3452.
[7] 耿建芳,周白丽.血栓调节蛋白与心脑血管疾病关系的研究进展[J].社区医学杂志,2011,9(4):35-37.
[8] 宋长广, 柳爱英, 贾玉东, 等. 凝血分子标志物检测在DIC早期临床诊断中的意义[J].国际检验医学杂志, 2009,30(8):792-794.
[9] 朱渝军, 黄显凯. 严重多发伤患者血浆凝血酶原片段1+2 D-二聚体血栓调节蛋白水平的变化及与DIC的关系[J].中国急救医学,2008,28(4):289-292.
[10]梁昌达,段荣,赖长城. 止凝血分子标志物测定在儿童感染性疾病并发 DIC时早期诊断的价值[J]. 实验与检验医学,2013,3(4):322-325.
[11]Morser J. Thrombomodulin links coagulation to inflammation and immunity[J]. Curr Drug Targets,2012,13(3):421-431.
[12]Mimuro J, Takahashi H, Kitajima I, et al. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) ondisseminated intravascular coagulation[J]. Thromb Res, 2013,131(5):436-443.
[13]Iba T, Aihara K, Watanabe S, et al. Recombinant thrombomodulin improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat LPS modle[J]. Thromb Res, 2013, 131(4):295-299.
[14]Nakahara M, Ito T, Kawahara K, et al. Recombinant thrombomodulin protects mice against histone-induced lethal thromboembolism[J]. PLoS One, 2013,8(9):e75961.
[15]Yamada Y, Maruyama J, Zhang E, et al. Effect of thrombomodulin on the developmentof monocrotaline-induced pulmonary hypertension[J]. J Anesth, 2014,28(1):26-33.
[16]Yamamoto M, Hori T, Hatakeyama N, et al. Use of Recombinant thrombomodulin in disseminated intravascular coagulation complicated hemophagocytic lymphohistiocytosis[J].Indian J Pediatr, 2014, 8(3) :288-291.
[17]罗方,黄连生,卢兴国,等. 出血性疾病患者的血浆血栓调节蛋白检测[J].现代实用医学,2003,15(4):242-243.
[18]赵志强, 邵建富. 失血性休克患者D二聚体、血栓调节蛋白水平的变化[J]. 河北医药,2010,32 (4): 439-440.
[19]Kashiwadate T, Miyagi S, Hara Y, et al. Recombinant human soluble thrombomodulin (ART-123) prevents warm ischemia-reperfusion injury in liver grafts from non-heart-beating donors[J]. Transplant Proc,2012,44(2):369-372.
[20]Ikezoe T, Yang J, Nishioka C, et al. Thrombomodulin protects endothelial cells from a calcineurin inhibitor-induced cytotoxicity by upregulation of extracellular signal-regulated kinase/myeloid leukemia cell-1 signaling[J]. Arterioscler Thromb Vasc Biol, 2012, 32(9):2259-2270.
[21]Nagasawa M, Ohkawa T, Endo A, et al. Early coagulation disorder after allogeneic stemcell transplantation is a strong prognostic factor for transplantation-related mortality,and intervention with recombinant human thrombomodulin improves the outcome: a single-center experience[J]. Int J Hematol, 2013, 98(5):533-542.
[22]Takagi Y, Kametaka H, Makino H, et al. A case of hepatocellular carcinoma treated by resection of metachronous rib metastasis after primary hepatectomy[J]. Gan To Kagaku Ryoho, 2012,53(2):235-239.
[23]Yamamoto S, Yagawa A, Toyama D, et al. Regulation of thrombomodulin expression during endothelium cell diseases[J]. Acta Haematol, 2013,129(1):62-64.
[24]Wu CT, Chang YH, Lin P, et al Thrombomodulin expression regulates tumorigenesis in bladder cancer[J]. BMC Cancer,2014, 14(1):375.
[25]Ikezoe T, Yang J, Nishioka C,et al. Thrombomodulin enhances the antifibrinolytic and antileukemic effects of all-trans retinoic acid in acute promyelocytic leukemia cells[J]. Exp Hematol, 2012,40(6):457-465.
[26]Yang J, Ikezoe T, Nishioka C, et al. Thrombomodulin-induced differentiation of acute myelomonocytic leukemiacells via JNK signaling[J]. Leuk Res, 2012,36(5):625-633.
[27]Ikezoe T, Takeuchi A, Isaka M, et al. Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascularcoagulation[J]. Leuk Res, 2012,36(11): 1398-1402.
[28]Yang L, Echevarria-Lima J, Monteiro RQ, et al. Thrombomodulin modulates cell migration in human melanoma cell lines[J]. Melanoma Res,2014, 24(1):11-19.
[29]Menschikowski M, Hagelgans A, Tiebel O, et al. Regulation of thrombomodulin expression in prostate cancer cells[J]. Cancer Letters, 2012,322(2):177-184.
[30]翟从永,胡建鹏,王键,等. 三种中药复方对脑缺血再灌注大鼠血浆血管性血友病因子和血栓调节蛋白影响的比较研究[J]. 中国中医急症,2008,17(10): 1419-1420.
[31]Horowitz NA, Blevins EA, Miller WM, et al. Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain[J]. Blood, 2011,118(10):2889-2895.
[32]Yokota N, Zarpellon A, Chakrabarty S, et al. Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice[J]. J Thromb Haemost, 2014,12(1):71-81.
[33]Chen LM, Wang W, Lee JC, et al. Thrombomodulin mediates the progression of epithelial ovarian cancer cells[J]. Tumour Biol,2013,34(6):3743-3751.
[34]Yin Q, Liu B, Chen Y, et al. The role of soluble thrombomodulin in the risk stratification and prognosis evaluation of septic patients in the emergency department[J]. Thromb Res, 2013,132(4):471-476.
[35]Tanaka J, Yamaguchi K, Ishikura H, et al. Bladder pain relief by HMGB1 neutralization and soluble thrombomodulin in mice with cyclophosphamide-induced cystitis[J]. Neuropharmacology, 2014,79:112-118.
[36]Festoff BW, Li C, Woodhams B, et al. Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication[J]. J Neurol Sci, 2012, 323(1/2): 61-65.
[37]Toda M, Shao Z, Yamaguchi KD, et al. Differential Gene Expression in Thrombomodulin (TM;CD141)+and TM2 Dendritic Cell Subsets[J]. PLoS ONE, 2013,8(8):e72392.